A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older | Zendy

Adrian Wagg | Zendy; Daniel Arumí | Zendy; Sender Herschorn | Zendy; J.C. Angulo | Zendy; François Haab | Zendy; Fady Ntanios | Zendy; Martin Carlsson | Zendy; Matthias Oelke | Zendy

Open Access

A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older

Author(s) -

Adrian Wagg,

Daniel Arumí,

Sender Herschorn,

J.C. Angulo,

François Haab,

Fady Ntanios,

Martin Carlsson,

Matthias Oelke

Publication year - 2016

Publication title -

age and ageing

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.014

H-Index - 143

eISSN - 1468-2834

pISSN - 0002-0729

DOI - 10.1093/ageing/afw252

Subject(s) - polypharmacy , medicine , overactive bladder , concomitant , placebo , adverse effect , logistic regression , odds ratio , alternative medicine , pathology

overactive bladder (OAB) is a common condition in older persons. Antimuscarinic treatment remains the mainstay of treatment of OAB but clinicians have been reluctant to prescribe this to older patients. This study examined efficacy and safety information from patients >65 in fesoterodine trials to reaffirm efficacy and to explore the relationships between treatment emergent adverse events (TEAEs), coexisting medication and co-morbidity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research